Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...
Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...
A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.
News Medical on MSN3d
NK cells with bispecific antibody yield high response rates in patients with lymphoma: Clinical trialA novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy ...
Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback